Innoviva - 8 Year Stock Split History | INVA

Stock split history for Innoviva since 2016. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.955B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $742.173B 107.29
Novo Nordisk (NVO) Denmark $575.795B 47.43
Johnson & Johnson (JNJ) United States $348.431B 13.82
Merck (MRK) United States $327.318B 59.55
AbbVie (ABBV) United States $287.978B 14.84
AstraZeneca (AZN) United Kingdom $235.262B 20.45
Novartis AG (NVS) Switzerland $198.534B 14.08
Pfizer (PFE) United States $145.074B 14.00
Sanofi (SNY) $124.533B 11.75